TVRD - Cara Therapeutics, Inc.
3.93
-0.090 -2.290%
Share volume: 53,450
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.26%
PREVIOUS CLOSE
CHG
CHG%
$4.02
-0.09
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-13-2024 | 08-14-2024 | 11-14-2024 | 03-11-2025 | 05-13-2025 | 08-14-2025 | 11-13-2025 | |
| Total revenue | 2.135 M | 991.000 K | 2.556 M | 1.455 M | 2.569 M | 0.000 | 0.000 | |
| Cost of revenue | 620.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 1.515 M | 991.000 K | 2.556 M | 1.455 M | 2.569 M | 0.000 | 0.000 | |
| -34.59% | 157.92% | -43.08% | 76.56% | -100.00% | nan% | |||
| Operating expenses | 28.780 M | 15.716 M | 7.837 M | 7.002 M | 4.955 M | 8.869 M | 5.938 M | |
| Selling general and admin | 6.816 M | 6.408 M | 6.475 M | 6.831 M | 4.636 M | 3.063 M | 2.335 M | |
| Research and development | 21.964 M | 9.308 M | 1.362 M | 171.000 K | 319.000 K | 5.806 M | 3.603 M | |
| Total expenses | 31.181 M | 18.297 M | 12.818 M | 6.878 M | 4.955 M | 8.869 M | 5.938 M | |
| -41.32% | -29.94% | -46.34% | -27.96% | 78.99% | -33.05% | |||
| Operating income | -29.666 M | -17.306 M | -5.988 M | -5.423 M | -2.386 M | -8.869 M | -5.938 M | |
| Ebit | -28.714 M | -18.106 M | -6.242 M | -5.456 M | -2.039 M | 3.790 M | -5.938 M | |
| Pretax income | -30.696 M | -20.016 M | -12.476 M | -8.077 M | -4.906 M | 4.167 M | -5.527 M | |
| -34.79% | -37.67% | -35.26% | -39.26% | -184.94% | -232.64% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -30.696 M | -20.016 M | -12.476 M | -7.679 M | -4.906 M | 4.167 M | -5.527 M | |
| 34.79% | 37.67% | 38.45% | 36.11% | 184.94% | -232.64% |